Skip to main content
. 2022 Aug 26;13:959938. doi: 10.3389/fphar.2022.959938

FIGURE 7.

FIGURE 7

The antitumor effect of myricetin in vivo. Myricetin was intratumorally injected to the mice every 2 days for 2 weeks. Body weight (A), images of xenografted tumors (B), and tumor volumes (B) were recorded. (C) Analysis of Ki67 and immunohistochemistry (cleaved-caspase-3 and GSDME) results from tumor samples. (D) Western blot analyses of GSDME from tumor samples and its corresponding statistical analysis. The results were presented as mean ± standard deviation (**p < 0.01, ***p < 0.001, when compared with the Mock).